Can anything stop this high-flying drugmaker?

In today’s Pharmaceutical Executive Daily, Eli Lilly reports positive topline Phase III results for retatrutide, the FDA expands Amgen’s Uplizna label into generalized myasthenia gravis subtypes, and ...

Eli Lilly shares have climbed in the double digits this year.

Businesses keep using AI tools to create cost-savings, but the true opportunity is not optimizing old workflows—it’s ...

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3% in the afternoon session after the ...

Here’s a closer look at the top pharmaceutical companies that have earned favorable rankings from Wolfe Research analysts. Johnson & Johnson takes the top spot with growth primarily driven by new ...

Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) ...

In today’s ACT Brief, we look at new evidence showing how targeted training can build research readiness at community cancer ...